Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbaglu in the Treatment of Hyperammonemia
NCT00843921Phase 3Unknown
- Start
- Aug 2008
- Primary completion
- Apr 2018
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of carglumic acid in hyperammonemia, N-acetylglutamate synthase deficiency, carbamoyl phosphate synthetase I deficiency (CPS1D) and 3 more. Primary endpoint: Rate of ureagenesis at 3 days. Status: unknown.
02
Drugs
carglumic acid
03
Conditions
hyperammonemiaN-acetylglutamate synthase deficiencycarbamoyl phosphate synthetase I deficiency (CPS1D)ornithine transcarbamylase deficiencypropionic acidemia (PA)
Beyond the preview
Go deeper on NCT00843921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843921.